02:22 PM EDT, 10/13/2025 (MT Newswires) -- Tvardi Therapeutics ( TVRD ) shares sank nearly 84% amid heavy trading after the company said Monday its phase 2 clinical trial of TTI-101 as a potential treatment for idiopathic pulmonary fibrosis failed to meet its goals.

Intraday trading volume jumped to over 5.55 million from a daily average of about 42,000.

Beyond Meat ( BYND ) said Monday its offer to exchange existing zero-interest convertible notes due in 2027 for new 7% secured notes due in 2030 and shares of common stock was subscribed with 96.92% of the holders tendering in for the exchange.

Shares slumped roughly 46% as intraday trading volume soared to nearly 117.5 million from a daily average of about 4.9 million.

Fastenal's ( FAST ) Q3 earnings came in below market estimates amid sluggish industrial production, while the company's sales rose in line with expectations.

Shares dropped 5.9% as intraday trading volume climbed to about 10.8 million from a daily average of roughly 6.3 million.

Price: 6.68, Change: -34.92, Percent Change: -83.94